Turnstone Biologics Inc.
787 Bank Street, 2nd Floor
About Turnstone Biologics Inc.
Turnstone Biologics is driven by science and innovation, with experienced leadership and world-renowned scientific founders in the field of oncolytics and immunotherapies.
Founders: Brain Lichty, John Bell, David Stojdl
CEO: Sammy Farah
CTO: Brain Lichty
Please click here for Turnstone Biologics job opportunities.
12 articles with Turnstone Biologics Inc.
Groundbreaking Research by Oncolytic Virus Pioneer Dr. John Bell will be Presented at the American Association for Cancer Research Tumor Immunology and Immunotherapy Meeting
Turnstone Biologics and the La Jolla Institute for Allergy and Immunology Enter into Strategic Collaboration for Personalized Neoantigen Immunotherapies
Turnstone Obtaining License to Neoantigen Identification Methodology Developed by the La Jolla Institute.
Turnstone Biologics announced its presentation at the upcoming investor conference
7/30/2018Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions.
Industry Veteran Jane Pritchett Henderson Named Chief Financial Officer
Turnstone Biologics announced that Sammy Farah, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference.
Turnstone Biologics Announces U.S. FDA Acceptance of IND for Immunotherapy Targeting HPV Positive Cancers
Phase I/II clinical trial studying MG1-HPV in combination with anti-PDL1 antibody in patients with cervical, oropharyngeal and other solid tumors to commence in Q2 2018
Dr. Burgess joins from Bristol-Myers Squibb, where he was senior vice president of development across multiple therapeutic areas.
Turnstone Biologics Strengthens Leadership Team With Appointment Of Kris Elverum As Chief Business Officer And Dr. José Manuel Otero As Vice President, Manufacturing And CMC
First Patient Treated In Turnstone Biologics's Lung Cancer Trial Combining Novel Viral Cancer Therapy With Approved Checkpoint Inhibitor